AR022395A1 - PEPTIDOS QUE ACTUAN COMO INHIBIDORES DE LA INTEGRINA ALFAvBETA6, LOS MEDICAMENTOS A BASE DE ESTOS PEPTIDOS, LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN AL MENOS UNO DE ESTOS PEPTIDOS, EL EMPLEO DE ESTOS PEPTIDOS PARA PREPARAR UN MEDICAMENTO, SECUENCIAS DE ADN RECOMBINANTE QUE CODIFICAN PARA UN FRA - Google Patents

PEPTIDOS QUE ACTUAN COMO INHIBIDORES DE LA INTEGRINA ALFAvBETA6, LOS MEDICAMENTOS A BASE DE ESTOS PEPTIDOS, LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN AL MENOS UNO DE ESTOS PEPTIDOS, EL EMPLEO DE ESTOS PEPTIDOS PARA PREPARAR UN MEDICAMENTO, SECUENCIAS DE ADN RECOMBINANTE QUE CODIFICAN PARA UN FRA

Info

Publication number
AR022395A1
AR022395A1 ARP990106525A ARP990106525A AR022395A1 AR 022395 A1 AR022395 A1 AR 022395A1 AR P990106525 A ARP990106525 A AR P990106525A AR P990106525 A ARP990106525 A AR P990106525A AR 022395 A1 AR022395 A1 AR 022395A1
Authority
AR
Argentina
Prior art keywords
peptides
prepare
integrin
formula
leu
Prior art date
Application number
ARP990106525A
Other languages
English (en)
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR022395A1 publication Critical patent/AR022395A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los péptidos de la formula (1) W1-X1n Arg X2 Asp Leu X3 X4 Leu X5 X6m-W2 en donde X1, X2, X3, X4, X5, X6 representan independientemente un resto deaminoácido, en el cual los aminoácidos se eligen independientemente del grupo formado por Ala, Asn, Asp, Arg, Cis, Gln, Glu, Gli, Fen, His lle, Leu, Lis, MetNle, homo-Fen, Fgli, Pro, Ser, Tr, Tri, Tir, o Val, y en el cual los aminoácidos mencionados también pueden estar derivados, W1 representa H o Ac, W2representa OH, OR, NHR, NR2 NH2, R representaalquilo de 1 a 6 átomos de C y n y m son independientemente un numero del 9 al 15. Un medicamento a base deestos péptidos que actua como inhibidor y permite combatir las enfermedades basadas en una expresion y funcion patologica de los receptores de integrinaAlfa v Beta6, en particular, la trombosis, el infarto de miocardio, las enfermedades cardíacas coronarias, la arteriosclerosis, los tumores, la osteoporosis,la fibrosis, las inflamaciones, las infecciones, la psoriasis, y también influye sobre los procesos curativos de cicatrizacion. El empleo de los péptidos deformula (1) para preparar un medicamento destinado a combatir las enfermedades mencionadas. Las composiciones farmacéuticas que contienen al menos unmedicamento a base de estospéptidos, junto con eventualmente excipientes y/o sustancias auxiliares y eventualmente también otras sustancias activas. El ADNrecombinante que contiene una secuencia que para codifica un fragmento peptídico que corresponde a un péptido de la formula (1).Un virus que contiene unaproteína de cápsula que presenta una secuencia que corresponde aun péptido de formula 1, y el empleo de este virus para preparar un medicamento destinadoa combatir las enfermedades basadas en una expresion y funcion patologica de los receptores de integrina alfav beta6.
ARP990106525A 1998-12-19 1999-12-17 PEPTIDOS QUE ACTUAN COMO INHIBIDORES DE LA INTEGRINA ALFAvBETA6, LOS MEDICAMENTOS A BASE DE ESTOS PEPTIDOS, LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN AL MENOS UNO DE ESTOS PEPTIDOS, EL EMPLEO DE ESTOS PEPTIDOS PARA PREPARAR UN MEDICAMENTO, SECUENCIAS DE ADN RECOMBINANTE QUE CODIFICAN PARA UN FRA AR022395A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19858857 1998-12-19

Publications (1)

Publication Number Publication Date
AR022395A1 true AR022395A1 (es) 2002-09-04

Family

ID=7891834

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990106525A AR022395A1 (es) 1998-12-19 1999-12-17 PEPTIDOS QUE ACTUAN COMO INHIBIDORES DE LA INTEGRINA ALFAvBETA6, LOS MEDICAMENTOS A BASE DE ESTOS PEPTIDOS, LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN AL MENOS UNO DE ESTOS PEPTIDOS, EL EMPLEO DE ESTOS PEPTIDOS PARA PREPARAR UN MEDICAMENTO, SECUENCIAS DE ADN RECOMBINANTE QUE CODIFICAN PARA UN FRA

Country Status (10)

Country Link
EP (1) EP1140989A1 (es)
JP (1) JP2002533064A (es)
CN (1) CN1335853A (es)
AR (1) AR022395A1 (es)
BR (1) BR9916323A (es)
CA (1) CA2355874A1 (es)
CZ (1) CZ20012212A3 (es)
NO (1) NO20013013L (es)
WO (1) WO2000037487A1 (es)
ZA (1) ZA200105929B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19929410A1 (de) * 1999-06-26 2000-12-28 Merck Patent Gmbh Inhibitoren des Integrins avß6
DE19933173A1 (de) * 1999-07-15 2001-01-18 Merck Patent Gmbh Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶
EP2287199B1 (en) 2002-03-13 2017-08-02 Biogen MA Inc. Anti-alpha V beta 6 antibodies
KR20050102634A (ko) 2003-02-06 2005-10-26 메르크 파텐트 게엠베하 펩티드성 설폰아미드
CN104072614B (zh) 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
GB0520068D0 (en) 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand
SG173364A1 (en) 2006-07-10 2011-08-29 Biogen Idec Inc Compositions and methods for inhibiting growth of smad4-deficient cancers
WO2008112004A2 (en) 2006-08-03 2008-09-18 Astrazeneca Ab ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
AU2007354317A1 (en) * 2006-10-19 2008-12-04 Biogen Idec Ma Inc. Treatment and prevention of chronic asthma using antagonists of integrin alphaVbeta6
WO2009093251A2 (en) * 2008-01-24 2009-07-30 Gavish-Galilee Bio Applications Ltd Reovirus vaccine based on sigma c protein sequence
WO2014007547A1 (en) * 2012-07-03 2014-01-09 Il Yang Pharm. Co.,Ltd. Novel peptides and use thereof
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
RU2769702C2 (ru) 2017-02-28 2022-04-05 Морфик Терапьютик, Инк. Ингибиторы интегрина avb6
EP3589285A4 (en) 2017-02-28 2020-08-12 Morphic Therapeutic, Inc. INHIBITORS OF INTEGRIN (ALPHA-V) (BETA-6)
EP3617206A1 (en) 2018-08-29 2020-03-04 Morphic Therapeutic, Inc. Integrin inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ219515A (en) * 1987-02-10 1989-09-27 Wellcome Found Fusion proteins comprising influenza virus ha and a nonnatural antigenic epitope

Also Published As

Publication number Publication date
CZ20012212A3 (cs) 2001-09-12
WO2000037487A1 (de) 2000-06-29
CA2355874A1 (en) 2000-06-29
ZA200105929B (en) 2003-03-18
NO20013013D0 (no) 2001-06-18
BR9916323A (pt) 2001-10-30
WO2000037487A8 (de) 2001-03-29
CN1335853A (zh) 2002-02-13
NO20013013L (no) 2001-06-18
JP2002533064A (ja) 2002-10-08
EP1140989A1 (de) 2001-10-10

Similar Documents

Publication Publication Date Title
AR022395A1 (es) PEPTIDOS QUE ACTUAN COMO INHIBIDORES DE LA INTEGRINA ALFAvBETA6, LOS MEDICAMENTOS A BASE DE ESTOS PEPTIDOS, LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN AL MENOS UNO DE ESTOS PEPTIDOS, EL EMPLEO DE ESTOS PEPTIDOS PARA PREPARAR UN MEDICAMENTO, SECUENCIAS DE ADN RECOMBINANTE QUE CODIFICAN PARA UN FRA
Chorev et al. Recent developments in retro peptides and proteins—an ongoing topochemical exploration
ES2346771T3 (es) Peptidos con multiples dominios a-helicoidales anfipaticos y procedimientos para su uso.
ES2271950T3 (es) Peptidos y peptidomimeticos con similitud estructural a p53 humana que activan la funcion p53.
ES2359616T3 (es) Péptidos citotóxicos modificados por restos voluminosos o lipofílicos.
DK0950096T3 (da) Anti-invasive og anti-angiogene urokinase-fragmenter og deres anvendelse
ES2544573T3 (es) Inhibidores diméricos de afinidad elevada de PSD-95 y su uso para el tratamiento del daño cerebral isquémico y del dolor
ES2406090T3 (es) Péptidos que tienen actividad farmacológica para tratar los trastornos asociados con la alteración de la migración celular, tal como el cáncer
RU95115239A (ru) Аналог эритропоэтина
EA021222B1 (ru) Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro
ES2427171T3 (es) Tratamiento de infecciones fúngicas y/o protistas
BRPI0207502B1 (pt) compostos, enanciômeros, composição farmacêutica, uso de compostos, e, processo para a fabricação de compostos
UY23561A1 (es) Procedimiento para la preparacion de tnf-muteinas
EA011037B1 (ru) Олигомерные пептиды и их применение для лечения вич инфекций
ES2227639T3 (es) Sintesis de analogos de pth y ptrp.
AR003121A1 (es) Antagonistas del receptor de adhesión, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y su empleo para preparar medicamentos y combatir enfermedades
ES2323963T3 (es) Peptido y/o proteinas y su uso para la fabricacion de un medicamento terapeutico y/o preventivo.
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
ES2322228T3 (es) Metodos de preparacion de peptidos.
JP2011523634A (ja) ペプチド、ペプチド模倣物およびそれらの誘導体、それらの製造、ならびに治療および/または予防活性のある医薬組成物を調製するためのそれらの使用
US20080171697A1 (en) Peptides Having For Example Antiangiogenic Activity and Applications Thereof In Therapeutics
DE69508382D1 (de) Peptomere mit erhöhter immunogenizität
AR029629A1 (es) Cefaiboles, nuevos antiparasitos obtenidos a partir de acremonium tubaki, procedimiento para su preparacion composiciones farmaceuticas y procedimiento para su preparacion y utilizacion de los mismos para preparar un medicamento.
AR020101A1 (es) Un antagonista peptido del receptor de uroquinasa humana, composicion farmaceutica que lo contiene, su uso para la manufactura de un medicamento y metodopara seleccionar un antagonista peptido adecuado.
JP2018526987A (ja) 腫瘍抑制ペプチド

Legal Events

Date Code Title Description
FA Abandonment or withdrawal